Basic scienceMinimal clinically important differences in Incontinence Quality-of-Life scores in stress urinary incontinence
Section snippets
Material and methods
Women with SUI were enrolled in two double-blind, controlled, randomized studies of duloxetine versus placebo.8, 9 One study randomized 553 women and the other 580 women at U.S. study sites. Predominant SUI was diagnosed using a clinical algorithm demonstrated to be 90.2% predictive of urodynamic stress incontinence.13
We used the Patient Global Impression of Improvement (PGI-I) rating as the anchor for this MCID analysis. It is a validated, single-item global rating of change scale that asks
Results
A total of 1133 women were randomized to duloxetine 20 mg/day (n = 138), 40 mg/day (n = 137), or 80 mg/day (n = 433) or placebo (n = 425). The mean age was 51.1 years; 50.9% had a body mass index of 28 kg/m2 or more; and 91% were white. The mean baseline IEF was 19.1/wk (SD 15.5), and the mean I-QOL score was 62.4 (SD 18.7).
Table I presents the I-QOL outcome data by PGI-I response category and demonstrates that the total and subscale scores had virtually identical between-treatment MCIDs,
Comment
This analysis has demonstrated that a reasonable guide for a clinically relevant increase in the I-QOL total score with treatment for women with SUI is ∼6.3 points (within-treatment MCID). The clinically relevant separation in improvements between two treatments is ∼2.5 points (between-treatment MCID). These thresholds are similar for the subscale scores, and the within-treatment MCID is similar to that previously reported in a study of 288 women with SUI and mixed urinary incontinence.7 Our
Conclusions
A score of 2.5 points can be considered a reasonable guide for the between-treatment and 6.3 points for the within-treatment MCID for the I-QOL total score. Statistically significant improvements in I-QOL scores should generally exceed both thresholds to be considered clinically important.
References (23)
- et al.
Evaluating the outcome of surgery for pelvic organ prolapse
Am J Obstet Gynecol
(1998) - et al.
Quality of life of persons with urinary incontinencedevelopment of a new measure
Urology
(1996) - et al.
Quality of life of women with urinary incontinencefurther development of the incontinence quality of life instrument (I-QOL)
Urology
(1999) - et al.
Duloxetine versus placebo in the treatment of stress urinary incontinence
Am J Obstet Gynecol
(2002) - et al.
Duloxetine vs. placebo in the treatment of North American women with stress urinary incontinence
J Urol
(2003) - et al.
Validation of a clinical algorithm indicative of urodynamic stress incontinence for use in large-scale clinical trials
J Urol
(2004) - et al.
Validation of two global impression questionnaires for incontinence
Am J Obstet Gynecol
(2003) - et al.
Comparative efficacy of behavioral interventions in the management of female urinary incontinence
Am J Obstet Gynecol
(1998) - et al.
Bladder neck support prosthesisa nonoperative treatment for stress or mixed urinary incontinence
J Urol
(1997) - et al.
Needle suspension procedures for female incontinence
Urol Clin North Am
(2002)
Cited by (39)
Effectiveness of Laparoscopic Pectopexy for Pelvic Organ Prolapse Compared with Laparoscopic Sacrocolpopexy
2023, Journal of Minimally Invasive GynecologyOnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: A 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial
2012, European UrologyCitation Excerpt :This study shows the positive impact of onabotulinumtoxinA doses ≥100 U for patients with idiopathic OAB refractory to standard medical therapy. The improvements in HRQOL scores observed with onabotulinumtoxinA in this study exceeded previously documented minimally or clinically important differences for the I-QOL (between-treatment MID of 2.5 points) [18] and the KHQ (change from baseline of ≥5 points) [19]. It is noteworthy that patients in this study reported both a disease-specific quality of life and a general HRQOL at baseline.
Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: A meta-analysis of clinical study reports
2017, CMAJCitation Excerpt :Duloxetine was better than placebo in terms of mean change in this score (mean difference 3.24, 95% CI 2.00 to 4.48, I2 = 5%; Figure 2). However, given that the published minimum clinically important difference for the Incontinence Quality of Life total score is 2.5,35 this difference may not be clinically important. Furthermore, the effect size for this outcome was small (standardized mean difference 0.24, 95% CI 0.15 to 0.33, I2 = 0%; Appendix 1).
This study was sponsored by Eli Lilly and Company and Boehringer Ingelheim.
- 1
I. Yalcin, K. Summers, K. Kinchen, and R.C. Bump are employees of, and hold stock in, Eli Lilly. D.L. Patrick is a paid consultant to Eli Lilly.